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Abstract
Background: The Neutrophil to lymphocyte ratio (NLR) has prognostic value in patients with a variety of cancers.
However, its prognostic significance in oral squamous cell carcinoma (OSCC) patients has not been fully explored.
The purpose of this study was to determine the clinical significance of NLR in patients with OSCC.
Methods: OSCC patients who underwent surgery following 5-fluorouracil (5-FU)-based chemoradiotherapy were
enrolled in this study. The associations between the NLR status and various clinicopathological features were
examined, and the effects of the NLR on the prognosis were evaluated. Analysis of circulating interleukin-6 (IL-6)
was carried out and correlation with NLR and C-reactive protein concentration (CRP) was examined.
Results: An elevated NLR was significantly correlated with advanced T-stage and poor response to chemoradiotherapy.
Moreover, a Cox regression analysis based on the disease-free survival (DFS) revealed the NLR status (hazard ratio, 2.013;
P = 0.041) and pathological response to chemoradiotherapy (hazard ratio, 0.226; P = 0.001) to be significant prognostic
factors in OSCC patients. Furthermore, circulating IL-6 was found to correlate with NLR and CRP.
Conclusion: The NLR is a potential biomarker for predicting the clinical response to 5-FU-based chemoradiotherapy and
the survival in OSCC patients, and the systemic inflammatory response may be potential target for improving patient’s
prognosis.
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Background
Oral cancer is one of the most common cancers [1]. The
survival rate of patients with oral cancer has not
improved despite improvements and innovations in
diagnostic techniques and treatments, and the prognosis
of OSCC remains poor, with a 5-year survival rate of ap-
proximately 50 % [2]. Therefore, in order to further
improve patient outcomes, it is imperative to investigate
novel markers for predicting the prognosis and guide
the therapeutic management of OSCC.
Increasing evidence suggests that the tumor micro-
environment plays an important role in determining the
biological behavior of cancers, such as proliferation,
invasion, metastasis and therapeutic resistance [3, 4]. In
recent years, it has become clear that cancer-associated
inflammation, in the form of local and systemic inflam-
matory responses, is a key factor of disease progression
and survival in several cancers [5, 6]. Among various
characteristics of the systemic inflammatory response,
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including the plasma CRP, hypoalbuminemia and Glasgow
Prognostic Score (GPS, which combines CRP and
albumin), as well as the absolute white cell count and
platelet/lymphocyte ratio (PLR), the NLR is one of
the most easily measurable parameters of the systemic
inflammatory response [7].
It has been demonstrated that an increased pre-
treatment NLR is associated with a poor clinical out-
come for various types of cancers, including colorec-
tal cancer [7], pancreatic cancer [8], small cell lung
cancer [9], breast cancer [10] and diffuse large B-cell
lymphoma [11]. Although the clinical significance of
the NLR has been revealed in various types of cancer,
there are few studies investigating the clinical signifi-
cance of the NLR in cases of head and neck carcin-
oma, including OSCC [12, 13]. In particular, the
relationship between the NLR and treatment response
in patients receiving chemoradiotherapy for OSCC
has not been elucidated.
Among various cytokines that mediate the systemic in-
flammatory response, IL-6 is known to be an important
cytokine that stimulates hepatocytes to induce acute-
phase proteins, including CRP, and elicits neutrophil
proliferation, thereby increasing the NLR [14, 15].
Recently, it has been suggested that targeting for IL-6
mediated signaling is a potential strategy for controlling
the systemic inflammatory response [7, 16], as well as
the malignant behavior of cancer cells themselves [17].
However, the relationship between the circulating
concentration of IL-6 and the status of the systemic
inflammatory response in OSCC patients has not yet
been fully examined.
Therefore, for the first time, we investigated the clin-
ical significance of the NLR and the correlation between
circulating IL-6 and the systemic inflammatory response
in OSCC patients treated with preoperative chemoradio-
therapy in the present study.
Methods
Clinical characteristics of the patients
In total, there were 124 patients with advanced OSCC
treated at Kumamoto University Hospital between
October 2003 and January 2009 whose clinical informa-
tion and laboratory parameters were available. Patients
with factors that could influence the NLR, such as con-
current infections, chronic inflammatory diseases, recent
treatment with steroids or previous treatment with
chemo- or radiotherapy were excluded. All patients were
treated preoperatively with chemoradiotherapy. Radio-
therapy was administered at a daily dose of 2.0 Gy five
times a week for 15 days. An oral fluorouracil anti-
cancer agent, S-1, was concurrently administered at a
dose of 80, 100 or 120 mg/day according to each pa-
tient’s body surface area for 14 days from the initiation
of radiotherapy. All tumors were staged according to the
TNM classification of the UICC (2002), and the degree
of differentiation was determined based on the grade
classification of the WHO. Using specimens obtained
during surgery, the histological response to chemoradio-
therapy was graded according to the criteria proposed
by Shimosato et al. [18], as follows: grade I, tumor struc-
tures are not destroyed; grade IIa, destruction of the
tumor structure is mild (i.e., ‘viable tumor cells’ are fre-
quently observed); grade IIb, destruction of the tumor
structure is severe (i.e., ‘viable tumor cells’ are few in
number); grade III, nonviable tumor cells are present
and grade IV, no tumor cells remain. The current study
followed the guidelines of the Ethics Committee of
Kumamoto University. The nature and aims of the study
were explained to all patients, who gave their written
informed consent for the research.
Follow-up
Patients underwent hematologic tests and assessments
of clinical symptoms every 2 weeks. The presence of a
recurrence was determined by means of imaging modal-
ities, including CT, MRI, US, and PET-CT. The patients
underwent at least one type of imaging examination at
intervals of 3–4 months during the first 2 years after
surgery, and at intervals of 4–6 months thereafter until
5 years after surgery.
Methods
Blood samples were collected before the administration
of preoperative chemoradiotherapy for a routine labora-
tory analysis of the full blood count, neutrophil count
and lymphocyte count. Briefly, the NLR was determined
by dividing the absolute neutrophil count by the abso-
lute lymphocyte count, and the NLR data were then di-
chotomized and divided into two groups as NLR-low
and -high. The value of NLR that best discriminated be-
tween good and poor survival, with the most significant
P-value according to the log-rank test, was determined
by testing all possible cutoffs. Peripheral blood samples
available for the assessment of the circulating concentra-
tions of IL-6 were collected from only 37 patients in our
present cohort. The blood samples for circulating IL-6
measurement were centrifuged and the serum was
stored at -80 °C before the analysis of IL-6. The circulat-
ing concentrations of IL-6 were measured using a
Human IL-6 Quantikine ELISA Kit (R&D Systems,
MN, US) according to the manufacturer’s instructions.
This study was approved by the ethics committee of
Kumamoto University.
Statistical analysis
The chi-square test was used to determine the associa-
tions between the pre-treatment NLR status and the
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clinical and pathological variables. Overall survival (OS)
and DFS were defined as the time from treatment initi-
ation (chemoradiotherapy) to the date of death from any
cause and the date of recurrence of cancer or death from
any cause, respectively. The Kaplan–Meier method was
used to estimate the probability of OS and DFS as a
function of time, and the statistical differences in the
survival of the subgroups of patients were compared
using the log-rank test. A multivariate survival analysis
was performed using the Cox regression model to study
the effects of the pre-treatment NLR status on the DFS.
Scatter plots were used to observe the associations be-
tween the circulating concentrations of IL-6 and NLR or
CRP, and relationships between these parameters were
investigated with Pearson’s correlation coefficient test.
All P-values were based on two-tailed statistical analyses,
and P-values of < 0.05 were considered to be statistically
significant (*P < 0.05 and ** P < 0.01). The statistical ana-
lyses were completed using the JMP 9 software program
(SAS Institute Inc., Cary, NC).
Results
Relationships between the pre-treatment NLR status and
clinicopathological characteristics
In order to elucidate the clinical significance of the
pre-treatment NLR in OSCC patients treated with
preoperative 5-FU-based chemoradiotherapy, we ex-
amined the correlations between the NLR status and
the clinicopathological variables. The median neutro-
phil count was 4200 per mm3, the median lympho-
cyte count was 1770 per mm3 and the median NLR
was 2.4 (95 % CI = 2.0–2.8). When the NLR was ana-
lyzed as a dichotomous variable, a cut-off point of 2.4
provided the strongest prognostic value in our data-
set, which included the average value (=2.7) and the
tertiles (Additional file 1: Figure S1 and Additional
file 2: Figure S2). This level was therefore chosen for
further study. The chosen cut-off point was consider-
ably close to the OSCC data that were previously re-
ported by Fang et al. [12]. The patients were further
divided into two groups depending on the NLR sta-
tus: 64 patients (51.6 %) had an NLR of ≥ 2.4 at
baseline (NLR-high), whereas 60 had a lower NLR
(NLR-low). Table 1 shows the distribution of the clin-
ical background characteristics of the studied patients
divided into the two groups (NLR-high and NLR-low)
according to the NLR. The frequency of NLR-high
patients was significantly higher among the cases who
showed an advanced T-stage and poor pathological
response to preoperative chemoradiotherapy (P = 0.016
and P = 0.038). There were no differences in the expres-
sion status of NLR according to age, gender, primary
tumor site, N-stage, clinical stage or differentiation. These
results indicate that the NLR status is associated with the
biological behavior of cancer cells, especially tumor
growth and resistance to preoperative chemoradiotherapy.
Relationships between the pre-treatment NLR status and
survival time
In order to assess the relationships between the pre-
treatment NLR status and survival time, the overall and
disease-free survival of the 124 OSCC patients were
Table 1 Correlation between the NLR status and
clinicopathological factors in 124 OSCC patients
Characteristics Total NLR status P-value
High Low
n (%) n (%)
124 64 (51.6) 60 (48.4)
Age (years)
Median 67.2 68.8 65.4
Range 28–87 39–85 28–87
≤ 65 51 22 (43.1) 29 (58.9) 0.114
> 65 73 42 (57.5) 31 (42.5)
Gender
Male 75 38 (50.7) 37 (49.3) 0.794
Female 49 26 (53.1) 23 (46.9)
Primary site
Tongue 35 18 (51.4) 17 (48.6) 0.958
Mandible 42 24 (57.1) 18 (42.9)
Maxilla 18 8 (44.4) 10 (55.6)
Oral floor 15 7 (46.7) 8 (53.3)
Buccal mucosa 14 7 (50.0) 7 (50.0)
T-stage
T1, T2 39 13 (33.3) 26 (66.6) 0.016*
T3 38 21 (55.3) 17 (44.7)
T4 47 30 (63.8) 17 (36.2)
N-stage
N0, N1 25 13 (52.0) 12 (48.0) 0.965
≥ N2 99 51 (51.5) 48 (48.5)
Clinical stage
III 38 20 (52.6) 18 (47.4) 0.880
IV 86 44 (51.2) 42 (48.8)
Differentiation
Well 99 49 (49.5) 50 (50.5) 0.348
Moderate 25 15 (60.0) 10 (40.0)
Pathological response
Grade≤ IIb (poor ~ partial response) 51 32 (62.7) 19 (37.3) 0.038*
Grade ≥ III (complete response) 73 32 (43.8) 41 (56.2)
Abbreviation: NLR neutrophil to lymphocyte ratio, OSCC oral squamous cell
carcinoma. The chi-square test was used to examine the relationships between
NLR status and clinicopathologic factors
*, P < 0.05
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analyzed using the Kaplan-Meier method. The median
OS from the time of diagnosis in the follow-up period
was 47.5 months (95 % CI = 39.2–55.9), while the me-
dian DFS in the follow-up period was 40.1 months
(95 % CI = 33.0–47.2). Twenty-eight patients died dur-
ing the follow-up period. The median OS in the
NLR-high group during the follow-up period was
46.2 months (95 % CI = 34.9–57.5), while that in the
NLR-low group was 51.1 months (95 % CI = 38.2–
64.1) (P = 0.069; Fig. 1a). The 5-year OS rate of the
NLR-high group tended to be lower than that of the
NLR-low group; however, there were no significant
differences between the two groups. The median DFS
in the NLR-high group during the follow-up period
was 36.5 months (95 % CI = 27.6–45.5), while that in
the NLR-group was 46.8 months (95 % CI = 35.0–
58.7) (P = 0.021; Fig. 1b). The 5-year DFS rate in the
NLR-high group was significantly lower than that in
the NLR-low group. Collectively, our data indicate
that the status of NLR may be a potential prognostic
Fig. 1 Relationships between the NLR and cancer-specific survival in patients with OSCC. In the Kaplan-Meier survival analysis of patients with oral
squamous cell carcinoma (OSCC), the patients were divided into two groups based on the NLR status (low and high groups). a Overall survival (OS) of
the 124 OSCC patients based on the NLR status. *, P < 0.05. b Disease-free survival (DFS) of the 124 OSCC patients based on the NLR status.
*, P < 0.05
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factor in patients with OSCC receiving 5-FU-based
chemoradiotherapy.
Multivariate analysis of prognostic factors
In order to determine the independent prognostic value of
the pre-treatment NLR for DFS, a multivariate analysis
was performed using a Cox proportional hazards regres-
sion model. After adjusting for the primary site, T-stage,
N-stage, tumor cell differentiation and pathological re-
sponse to chemoradiotherapy, the influence of the NLR
on DFS (hazard ratio = 2.013, 95 % CI = 1.029–4.144;
P = 0.041) remained. In addition, the pathological response
to preoperative chemoradiotherapy was also a significant
prognostic factor (hazard ratio, 0.226; 95 % CI, 0.093–
0.527; P = 0.001) (Table 2). Therefore, we assumed that the
NLR status, as well as the pathological response to pre-
operative chemoradiotherapy, potentially affects the prog-
nosis and is a potential independent prognostic factor in
OSCC patients receiving 5-FU-based chemoradiotherapy.
Relationships between the circulating concentration of
IL-6 and pre-treatment markers of the systemic
inflammatory response
In order to explore the potential relationships between
the circulating IL-6 levels and systemic inflammatory
response-related characteristics, such as NLR and CRP,
in the OSCC patients, the circulating concentrations of
IL-6 in pre-treatment serum were measured using
ELISA and examined the correlations with the NLR and
CRP values. On Pearson’s correlation coefficient test,
there were significant associations between the circulat-
ing concentrations of IL-6 and the NLR (Fig. 2a, r = 0.33,
P = 0.047) and CRP (Fig. 2b, r = 0.34, P = 0.038). These
results suggest that the circulating IL-6 level may have
the potential to mediate the systemic inflammatory re-
sponse in OSCC patients.
Discussion
In the present study, we found three major findings.
First, an increased pre-treatment NLR was correlated
with the T-stage and resistance to 5-FU-based chemora-
diotherapy in patients with OSCC. Second, an increased
pre-treatment NLR was correlated with a shorter DFS in
the OSCC patients who underwent preoperative 5-FU-
based chemoradiotherapy. Finally, there was a positive
correlation between the circulating IL-6 concentration
in the peripheral blood and the NLR value. To the best
of our knowledge, this is the first study to describe the
use of the NLR in the OSCC setting in patients receiving
5-FU-based chemoradiotherapy to provide useful infor-
mation regarding resistance to chemoradiotherapy and
prognostication. Furthermore, a positive correlation be-
tween the circulating IL-6 and the systemic inflamma-
tory response in OSCC was demonstrated for the first
time.
There are several explanations for the relationship be-
tween an elevated NLR and aggressive phenotypes in
cases of cancer. Generally, an elevated NLR reflects an
increased neutrophil count and/or decreased lymphocyte
count. Circulating neutrophils contain and secrete vari-
ous cytokines, chemokines, proteases and growth fac-
tors, including vascular endothelial growth factor [19],
platelet-derived growth factor, fibroblast growth factor
[20], matrix metalloproteinase [21] and IL-6 [22]. These
molecules create a microenvironment for extracellular
matrix remodeling, endothelial cell migration and tumor
cell dissociation [23]. Moreover, it has been shown that
neutrophils may suppress the cytolytic activity of a var-
iety of immune cells, such as lymphocytes, activated T
cells and natural killer cells under the co-culture condi-
tions of neutrophils and lymphocytes obtained from
healthy donors, and the degree of suppression is closely
associated with the number of neutrophils [24, 25].
Collectively, an elevated NLR may be associated with
Table 2 The results of a multivariate regression analysis for
predicting the disease-free survival of 124 OSCC patients
Variables Assigned score Hazard ratio (95 % CI) P-value
Primary site










N0, N1 0 1.844 (0.701–5.063) 0.217
≥ N2 1
Differentiation
Well 0 0.636 (0.267–1.348) 0.249
Moderate 1
Pathological response





Low 0 2.013 (1.029–4.144) 0.041*
High 1
Abbreviations: CI confidence interval, NLR neutrophil to lymphocyte ratio,
OSCC oral squamous cell carcinoma
*, P < 0.05
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establishment of the tumor microenvironment and low
immunocompetence in cancer patients with OSCC as
well as subsequently induced tumor growth [4]. These
observations and hypothesis strongly support our results
showing that an elevated NLR (i.e., elevated systemic
inflammatory response) contributes to tumor progres-
sion in patients with OSCC.
Recently, the clinical significance of the NLR in pa-
tients receiving chemotherapy as well as surgical resec-
tion has been reported. Chua et al. [7] reported the use
Fig. 2 Relationship between the circulating concentrations of IL-6 and the pre-treatment NLR and CRP in the 37 patients with OSCC. Scatter plots
of the circulating IL-6 concentration and indicators of the systemic inflammatory response. a Relationship between the circulating concentrations
of IL-6 and the pre-treatment NLR. The x-axis indicates the circulating IL-6 concentration and the y-axis shows the value of NLR. The correlation
was investigated using Pearson’s correlation coefficient test. *, P < 0.05. b Relationship between the circulating concentrations of IL-6 and the
pre-treatment CRP. The x-axis indicates the circulating IL-6 concentration and the y-axis shows the value of CRP. The correlation was investigated
using Pearson’s correlation coefficient test. *, P < 0.05
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of the NLR as a marker of the systemic inflammatory re-
sponse and an independent predictor of the clinical
benefit, progression and survival in patients receiving
chemotherapy for metastatic colorectal cancer. Santoni
et al. [26] revealed that the NLR is an independent prog-
nostic factor for metastatic renal cell carcinoma among
patients treated with molecular targeted therapy. In
cases of advanced non-small cell lung cancer and high-
grade serous epithelial ovarian cancer, the relationship
between an elevated NLR and a poor response to
chemotherapy was also recently reported [27, 28]. The
results of the present study are in line with those of
these previous data and suggest that the pre-treatment
NLR is potentially a useful predictor of the response to
5-FU-based chemoradiotherapy. In addition, our data in-
dicate the presence of chemoradioresistance mechanisms
mediated by the systemic inflammatory response in
OSCC as well as other malignancies.
Notably, an elevated NLR in OSCC patients is signifi-
cantly correlated not only with a poor response to
chemoradiotherapy, but also a shorter DFS (Fig. 1b). Al-
though the reason why the NLR was not found to cor-
relate with the OS is unclear, the potential correlation
between the NLR and non-malignant diseases, such as
myocardial infarction, in which the systemic inflamma-
tion response has been implicated as a major contribut-
ing factor [29], may possibly affect our results. On the
other hand, because the NLR is significantly associated
with the pathological response to preoperative chemora-
diotherapy, the difference in the survival rate in DFS
may be partly explained by differences in the treatment
response to preoperative chemoradiotherapy between
the low and high NLR groups. Consistent with our
results, it has been reported that an elevated NLR is cor-
related with a worse prognosis in many malignancies
[7–11]. Moreover, Fang et al. [12] reported that an ele-
vated NLR is significantly associated with a worse
disease-free and overall survival in OSCC patients.
Nevertheless, to the best of our knowledge, there are no
previous studies investigating patients receiving chemo-
radiotherapy. This is the first report of the association
between the NLR status and the prognosis in patients
with OSCC receiving chemoradiotherapy. In the setting
of OSCC, treatment options combining anticancer agents
or chemoradiotherapy, including preoperative therapies,
are important treatment strategies [30–32], and investigat-
ing good prognostic markers in patients receiving these
treatment modalities is thus valuable. The results of the
present study suggest that the NLR may be useful for
making treatment decisions in OSCC patients receiving
chemo- and/or chemoradiotherapy. Because the NLR is a
simple, readily available and robust laboratory variable, we
assume that this concept may be widely accepted in vari-
ous types of cancer and in various countries.
Although the molecular mechanisms of therapeutic re-
sistance have not been fully elucidated, the pre-existing
state of the tumor microenvironment established by the
systemic inflammatory response may provide cancer
cells with advanced malignant phenotypes and immune
suppressive conditions, which could determine the re-
sponse to chemotherapy. Recently, it has been suggested
that IL-6, which is derived from cancer cells as well as
from tumor stromal cells, such as cancer-associated fi-
broblasts and infiltrating immune cells [7, 33], may
modulate both the local tumor microenvironment and
the chronic systemic inflammatory response by causing
the differentiation of tumor-infiltrating monocytes into
immunosuppressive, M2-like macrophages [34] and by
attracting regulatory T cells [35] in patients with cancer,
thereby allowing cancer cells to acquire an advanced
malignant phenotype. In OSCC, we previously demon-
strated that tocilizumab, a humanized anti-IL-6R anti-
body, may be effective for OSCC treatment, at a
minimum by inhibiting angiogenesis and lymphangio-
genesis in vitro and vivo [17, 36]. Taken together, our
findings suggest that IL-6 is a potential treatment target
for OSCC, improving the outcomes of chemoradiother-
apy and prognosis of patients with OSCC by operating
on the local and systemic inflammatory response initi-
ated by tumor- and/or stromal cell-derived IL-6. There-
fore, the suppression of circulating IL-6 levels with
tocilizumab may enhance the immune response and
sensitize OSCC cells to chemoradiotherapy, thereby
resulting in an improvement of the clinical outcomes of
patients with refractory OSCC.
There are some limitations associated with this study.
First, this was a retrospective study, which is susceptible
to bias in both data selection and analysis. Second, the
NLR differs among individuals and may be influenced by
general conditions and drugs that could not be
accounted for in this study. Third, the present data were
obtained from patients who were treated with modest
doses of 5-FU-based chemoradiotherapy and surgery.
Further investigation will therefore be needed to deter-
mine whether our results can be applied to all OSCC pa-
tients. Despite these limitations, our findings suggest
that an elevated NLR contributes to resistance to
chemo- and/or chemoradiotherapy and a poor prognosis
in patients with OSCC. In addition, the status of the
NLR may be useful for making treatment decisions to
improve the survival of OSCC patients. Further studies
are needed to determine the resistance mechanisms of
chemoradiotherapy underlying an elevated NLR and to
adequately assess the potential role of NLR in guiding
treatment decisions. Furthermore, the therapeutic effi-
cacy of targeting IL-6 must be assessed to overcome
chemoradioresistance and confirm the clinical signifi-
cance of our findings.
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Conclusions
Our findings reported herein demonstrated that pre-
treatment NLR is a potential biomarker for predicting
theclinical response to 5-FU-based chemoradiotherapy
and the survival in OSCC patients, and the systemicin-
flammatory response may be potential target for improv-
ing patient's prognosis.
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and cancer-specific survival in patients with OSCC. In the Kaplan-Meier
survival analysis of patients with oral squamous cell carcinoma (OSCC),
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124 OSCC patients based on their NLR status. (JPG 867 kb)
Additional file 2: Figure S2. The relationship between the NLR status
and cancer-specific survival in patients with OSCC. In the Kaplan-Meier
survival analysis of patients with oral squamous cell carcinoma (OSCC),
the patients were divided into three groups based on their NLR status
(Tertiles 1, 2 and 3). (A) The overall survival (OS) of the 124 OSCC patients
stratified by their NLR status. (B) The disease-free survival (DFS) of the 124
OSCC patients stratified by their NLR status. (JPG 974 kb)
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